Our results suggest a significant association between stathmin and the clinical stages of tumours, with upregulation of stathmin in the advanced stages (III and IV) of OSCC, which may result in tumour aggressiveness and the progression of OSCC. The gene discussed is STMN1; the disease is neoplasm.